AGO2 and diabetic kidney disease: A novel LncRNA, MEG3, is upregulated and promotes cell fibrosis and inflammatory in response to DKD by suppressing miR-181a and targeting the aforementioned genes, Egr-1 and TLR4. The interaction of LncRNA MEG3 with miR-181 is not only through sponging by competing with endogenous RNA mechanisms, but direct targeting by and in an Argonaute (Ago)2-dependent manner [127].